Lamotrigine (Epilepsy)

Study	Exclusion reasons	Rmk	Reference
Husebye (Lamotrigine) (Controls unexposed, sick), 2018		EXCLUDED: completely overlapped by Husebye et al. 2020 (same cohort, older children for neurodevelopmental outcomes). For those groups, results are only available according to folic acid intake.	Husebye Neurology 2018; 91:e811-e821 10.1212/WNL.0000000000006073
Husebye (Lamotrigine) (Controls unexposed, disease free), 2018		EXCLUDED: completely overlapped by Husebye et al. 2020 (same cohort, older children for neurodevelopmental outcomes). For those groups, results are only available according to folic acid intake.	Husebye Neurology 2018; 91:e811-e821 10.1212/WNL.0000000000006073
Vajda, 2018		Overlapping between Vajda 2024a (1999 - 2023) and Vajda 2018 (1999 - 2016) based on the same register and for the almost same outcome (with or without elective termination) => Use of Vajda 2024a because accounting for more relevant confounders.	Vajda Acta Neurol Scand 2018; 137:20-23 10.1111/ane.12816
Wiggs, 2020	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: Overlapping: Totally included in Madley-Dowd 2024. Children who were multiples were dropped. Crude data are not specified for monotherapy exposure. HR's results choose thanks to author's email.	Wiggs Neurology 2020; 95:e3232-e3240 10.1212/WNL.0000000000010993
Elkjaer, 2018	repeat population groups, duplicate reports (most recent study included)	Overlapping: this publication totally included the data of Elkjaer, 2018, for an higher academic grade => use of Ren 2023.	Elkjaer JAMA Neurol 2018; 75:663-671 10.1001/jamaneurol.2017.5035
Meador, 2021	repeat population groups, duplicate reports (most recent study included)	Overlapping: Meador 2021 and 2023 used the same cohort in order to study the same outcome, at 2 different ages (=> use of the data on the older children, i.e Meador 2023).	Meador JAMA Neurol 2021; 78:927-936 10.1001/jamaneurol.2021.1583